[1] Food labeling: health claims;soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule[J]. Fed Regist, 1999, 64(206):57700-57733. [2] Cooke GM. A review of the animal models used to investigate the health benefits of soy isoflavones[J]. J AOAC Int, 2006, 89(4):1215-1227. [3] 吴葆杰, 张世玲. 调血脂及抗动脉粥样硬化药的筛选法[M] 徐叔云, 卞如濂, 陈修, 主编. 药理实验方法学. 2 版. 北京:人民卫生出版社, 1991:1047-1051. [4] 韩玲译. 抗动脉粥样硬化作用[M] Vogel HG, 等编著, 杜冠华等译. 药理学实验指南—新药发现和药理学评价. 1 版. 北京:科学出版社, 2001:777-809. [5] Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, is of lavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee[J]. Circulation, 2006, 113(7):1034-1044. [6] Yamakoshi J, PiskulaMK, Izumi T, et al. Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits[J]. J Nutr, 2000, 130(8):1887-1893. [7] Makela SI, Pylkkanen LH, Santti RS, et al. Dietary soybean may be antiestrogenic in male mice[J]. J Nutr,1995, 125(3):437-445. [8] Fuchs D, Erhard P, Turner R, et al. Genistein reverses changes of the proteome induced by oxidized-LDL in EA. hy 926 human endothelial cells[J]. J Proteome Res, 2005, 4(2):369-376. [9] Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol[J]. Metabolism, 1992, 41(10):1110-1114. [10] Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans[J]. Am J Clin Nutr, 2000, 72(2):395-400. |